Loading
Colorectal Cancer Treatments and Studies / Esophageal Cancer Research and Treatment · Journal article
Cancers · August 18, 2026
A consensus or society position rather than new primary data.
This is a narrative review of biological and targeted therapies in gastrointestinal cancers, covering immune checkpoint inhibitors, HER2-directed agents, antiangiogenic and anti-EGFR therapies, and emerging molecular targets. The review emphasizes a shift toward biomarker-guided, individualized care and highlights that clinical efficacy alone is insufficient for clinical adoption—regulatory approval, reimbursement, access to testing, and multidisciplinary care infrastructure are equally critical.
Narrative review. Patients with esophageal, gastric and gastroesophageal junction, colorectal, pancreatic, hepatocellular, and biliary tract cancers.
Therapies reviewed include immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4; HER2-directed monoclonal antibodies and antibody–drug conjugates; antiangiogenic and anti-EGFR therapies Emerging strategies involve CLDN18.2, FGFR2b, and tumor-agnostic alterations such as NTRK fusions Clinical decision-making is moving beyond organ- and stage-based approaches toward biomarker-guided care
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that adoption of new GI cancer therapies depends not only on efficacy but also on regulatory status, reimbursement, molecular testing availability, and access to specialized multidisciplinary care. Clinical decisions should integrate tumor biology, resectability, molecular eligibility, toxicity profile, and local treatment access.
A narrative review synthesizing established and emerging biological and targeted therapies across multiple gastrointestinal cancer types, intended to inform clinical decision-making in a rapidly evolving treatment landscape.
As stated by the source record.
Clinicians should recognize that adoption of new GI cancer therapies depends not only on efficacy but also on regulatory status, reimbursement, molecular testing availability, and access to specialized multidisciplinary care. Clinical decisions should integrate tumor biology, resectability, molecular eligibility, toxicity profile, and local treatment access.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gastrointestinal (GI) cancers represent a diverse group of malignancies that remain a major cause of cancer-related morbidity and mortality worldwide. Their management is increasingly complex, reflecting differences in tumor biology, anatomical location, stage, and molecular profile. In recent years, advances in molecular diagnostics, immunotherapy, and targeted treatment have moved clinical decision-making beyond a purely organ- and stage-based approach toward more individualized, biomarker-guided care. This narrative review summarizes established and emerging biological and targeted therapies used in esophageal, gastric and gastroesophageal junction, colorectal, pancreatic, hepatocellular, and biliary tract cancers. It focuses on immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4; HER2-directed monoclonal antibodies and antibody–drug conjugates; antiangiogenic and anti-EGFR therapies; and newer strategies involving CLDN18.2, FGFR2b, and tumor-agnostic alterations such as NTRK fusions. The review also considers the predictive biomarkers used to guide treatment selection and the growing integration of systemic therapy with surgery in neoadjuvant, perioperative, adjuvant, and conversion settings. However, clinical efficacy alone does not determine whether new treatments become part of routine practice. Regulatory approval, reimbursement, access to molecular testing, and the availability of specialized multidisciplinary care are equally important. The rapidly evolving treatment landscape for GI cancers therefore requires clinical decisions that account for tumor biology, anatomical resectability, molecular eligibility, expected benefit, treatment-related toxicity, and local access to therapy. Expanding access to comprehensive biomarker testing and effective molecularly guided treatments will be essential to translate progress in precision oncology into more personalized and equitable care for patients with GI cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.